STATES CHRONICLE – New cholesterol treatment is bound to reverse heart diseases. Patients who have issues with their cholesterol levels might be encouraged to give up swallowing pills and get a shot three times per year to control their cholesterol. Researchers have tested a new treatment known as Inclisiran which is prone t o reduce the use of pills.
Based on the results of clinical trials, the injection delivers an active substance in the body which will last for 4 to 6 months. Dr. Kausik Ray, a professor of public health at Imperial College London England, has asserted that the new cholesterol treatment generated significant reductions in LDL cholesterol. In this way, the treatment could also be helpful in treating cardiovascular diseases.
The long lasting outcome will also be useful in preventing heart illnesses, preventing the arteries from hardening. The risks of stroke and heart attack will significantly drop. The results of the new medical trial were discussed on November 15 at the annual meeting of the American Heart Association in New Orleans. Before asking for the approval of the US Food and Drug Administration, the treatment will need another analysis.
Heart doctors claimed that statin medicines like Crestor (rosuvastatin) and Lipitor (atorvastatin) are essential components of the pills used to treat high cholesterol. Unfortunately, these substances are limited. At the meeting which took place on November 15, there was presented another clinical trial. It demonstrated that the mixing between the materials part of the Inclisiran’s class and statins could decrease the levels of LDL cholesterol to insignificant levels.
When a PCSK9 inhibitor known as Repatha (evolocumab) is combined with a statin, the new cholesterol treatment was able to reduce the cholesterol levels by approximately 60% more than the reduction registered by statins alone. Dr. Steven Nissen, the lead researcher of the study, is the chair of cardiovascular medicine at the Cleveland Clinic in Ohio.
By using ultrasound scans, researchers were able to determine that the low cholesterol levels registered after delivering the treatment were bound to decrease the arthritis cases in 4 out of 5 patients. The study which used Repatha involved approximately 846 patients who suffered from coronary artery illness. Half of the patients were treated only using statins, while the other half received a mixture of statins and the PCSK9 inhibitor. Almost 81% of the patients who were part of the second half registered a reduction or the arterial plaque.
Image courtesy of: pixabay